Sana Biotechnology, Inc. (SANA) Stock Price & Analysis
Sana Biotechnology, Inc. (SANA) rose 4.83% to USD 2.82 as of June 10, 2026 at 05:12 UTC, according to Nexqual real-time market data.
SANA last closed at USD 2.69; the session ranged USD 2.65–2.92 on volume of 8,697,513 shares. Market capitalization is $784.78M, with a 52-week range of USD 2.41–6.55 (NMS). Source: Nexqual, June 10, 2026 at 05:12 UTC.
Key Statistics (as of June 10, 2026 at 05:12 UTC)
| Price | USD 2.82 |
|---|---|
| Change | ▲ 4.83% (up) |
| Previous Close | USD 2.69 |
| Open | USD 2.73 |
| Day Range | USD 2.65 – 2.92 |
| 52-Week Range | USD 2.41 – 6.55 |
| Volume | 8,697,513 shares |
| Market Cap | $784.78M |
| Exchange | NMS |
Technical Analysis (SANA)
Nexqual's technical model rates SANA "SELL" based on 3 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.67 (oversold) |
| vs SMA50 | Below (USD 3.23) |
| MACD | -0.12 (negative) |
Analyst Ratings (SANA)
Wall Street analysts rate SANA "Strong Buy" based on 7 analysts, with a mean price target of USD 8.57 (range USD 7–12), per Nexqual as of June 10, 2026 at 05:12 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 8.57 |
| High Target | USD 12 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (SANA)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.12 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.14 vs est -0.15 ▲ beat |
| 2025-12-31 | USD -0.16 vs est -0.13 ▼ miss |
| 2025-09-30 | USD -0.15 vs est -0.19 ▲ beat |
| 2025-06-30 | USD -0.16 vs est -0.21 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:12 UTC.
Financials & Fundamentals (SANA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -147.41% |
| Debt / Equity | 69.3 |
| Current Ratio | 1.3 |
| Total Cash | $101.14M |
| Total Debt | $82.63M |
| Free Cash Flow | $-29.72M |
Source: Nexqual, June 10, 2026 at 05:12 UTC.
Financial Health Score (SANA)
Nexqual rates Sana Biotechnology, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:12 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $101M cash vs $83M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$133M |
| Efficiency | Critical — ROE -147%, ROA -27.5% |
Ownership (SANA)
| Insider Ownership | +6.51% |
|---|---|
| Institutional Ownership | +82.83% |
| Shares Outstanding | 278.29M |
| Float | 169.91M |
| Short % of Float | +25.16% |
Source: Nexqual, June 10, 2026 at 05:12 UTC.
Leadership (SANA)
Sana Biotechnology, Inc. is led by Steven D. Harr (age 55), President, CEO & Director, per Nexqual as of June 10, 2026 at 05:12 UTC.
| President, CEO & Director | Steven D. Harr (age 55) |
|---|---|
| Executive VP & CFO | Brian D. Piper (age 53) |
| Executive VP & Chief Scientific Officer | Dhavalkumar D. Patel (age 64) |
Major Backers & Investors (SANA)
Notable institutional backers of Sana Biotechnology, Inc. include FMR, LLC, Flagship Pioneering LLC, Fidelity, according to Nexqual as of June 10, 2026 at 05:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 13.45% |
| Flagship Pioneering LLC | 8.98% |
| Fidelity | 6.96% |
| Canada Pension Plan Investment Board | 3.67% |
| Baillie Gifford | 2.37% |
| Marex Group Plc | 1.44% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.99% |
| State Street | 6.46% |
| Vanguard Group | 5.27% |
| Geode Capital | 1.5% |
Source: Nexqual, June 10, 2026 at 05:12 UTC.
From Sana Biotechnology, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- We expect to submit an IND for SC451 and begin our Phase 1 trial as early as this year. 6   With respect to our in vivo cell engineering research efforts, we have advanced from our earlier SG299 in vivo CAR T candidate to an improved next-generation product candidate, SG293, both of which use our proprietary fusogen-based delivery platform.
- We have built significant internal capabilities across a wide range of areas focused on solving the most critical limitations in engineering cells including: • Stem Cell and Disease Biology .
- To demonstrate applicability in the context of the autoimmunity seen in people with T1D, we developed a proprietary mouse model in-house with human immune cells from a T1D patient.
- The safety data, secondary endpoints, dosing rationale, clinical outcomes, and immune analysis from the treated patient are discussed below in the section titled "Pancreatic Islet Cell Program." 9   In vivo CD19-Directed CAR T Cells SG293 Our in vivo CAR T pipeline has advanced beyond our earlier constructs, such as SG299, to our next-generation product candidate, SG293, which leverages our proprietary fusogen delivery platform to enable direct, in-patient generation of CAR T cells.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VOR | Vor Biopharma Inc. | USD 13.28 | ▲ 0.91% |
| CRBU | Caribou Biosciences, Inc. | USD 1.84 | ▼ 4.17% |
| RLAY | Relay Therapeutics, Inc. | USD 14.09 | ▲ 4.22% |
| NKTX | Nkarta, Inc. | USD 2.45 | ▼ 2.39% |
| CCCC | C4 Therapeutics, Inc. | USD 3.58 | ▼ 7.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:12 UTC. This page is informational and not investment advice.